PHAT (Phathom Pharmaceuticals) Buyback Yield %: -14.50 (As of Jul. 02, 2026)


PHAT Phathom Pharmaceuticals Inc PHAT
23 GF Score
Price $11.09
! 3 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals Buyback Yield %?

Phathom Pharmaceuticals PHAT +5.17% 23 Buyback Yield % is -14.50 as of Jul. 02, 2026. GuruFocus rates PHAT with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 745 Biotechnology companies, Phathom Pharmaceuticals ranks worse than 59.87% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Phathom Pharmaceuticals's current buyback yield was -14.50%.

Phathom Pharmaceuticals Buyback Yield % Related Terms

Phathom Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Phathom Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals Buyback Yield % Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial 0.00 -5.29 -29.37 -21.89 0.00

Phathom Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -13.82

PHAT vs GERN, ODTX, SPRY: Buyback Yield % Comparison

For the Biotechnology subindustry, Phathom Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phathom Pharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's Buyback Yield % falls into.


PHAT
23GF Score
Phathom Pharmaceuticals Inc PHAT
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phathom Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Phathom Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 1184.84121
=0.00%

Phathom Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 121.974) / 882.60062
=-13.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -14.50 mean?
Phathom Pharmaceuticals (PHAT) has a Buyback Yield % of -14.50 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Phathom Pharmaceuticals and its competitors. According to the industry distribution chart, Phathom Pharmaceuticals ranks #446 out of 745 companies in the Biotechnology industry, placing it in the top 59.9%.
Is Phathom Pharmaceuticals' Buyback Yield % too high?
Phathom Pharmaceuticals' current Buyback Yield % is -14.50. Based on the distribution chart, Phathom Pharmaceuticals ranks #446 out of 745 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Phathom Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Buyback Yield % compare to GERN and ODTX?
According to the Biotechnology industry distribution chart, Phathom Pharmaceuticals ranks #446 out of 745 companies for Buyback Yield %. This places Phathom Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current Buyback Yield % is -14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Phathom Pharmaceuticals (PHAT) has a current Buyback Yield % of -14.50. The current Buyback Yield % is -14.50. Phathom Pharmaceuticals' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Buyback Yield % is -14.50 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
23GF Score

Get the complete analysis for PHAT

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.09
Price